Pharma and Biotech Daily: Analyzing the Impact of Trump's Win on the Industry

Pharma and BioTech Daily

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. Analysts are expressing mixed reactions to Donald Trump's election victory. There are potential positives for the biopharma industry, such as a more friendly FTC for M&A deals. However, concerns have been raised about what role Robert F. Kennedy, Jr. might play in healthcare under Trump's administration. Moving on to recent news, Catalent missed fiscal Q1 revenue expectations and there is growing opposition to Novo Holdings' acquisition of Catalent. Novo Nordisk also missed overall Q3 revenue expectations, but exceeded sales forecasts for the weight loss drug Wegovy. Gilead and Arcellx are highlighting the best-in-class potential for CAR T therapy in multiple myeloma. Overall, Trump's win poses more questions than answers for the biopharma industry, with uncertainties about the future regulatory environment and potential impacts on healthcare policies.